| Literature DB >> 31757584 |
Nur Shabrina Amirruddin1, Blaise Su Jun Low1, Kok Onn Lee2, E Shyong Tai3, Adrian Kee Keong Teo4.
Abstract
Pancreatic β-cells are responsible for maintaining glucose homeostasis. Therefore, their dysregulation leads to diabetes. Pancreas or islet transplants can be used to treat diabetes but these human tissues remain in short supply. Significant progress has now been made in differentiating human pluripotent stem cells (hPSCs) such as human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) into pancreatic β-like cells for potential cell replacement therapy. Additionally, these hPSC-derived β-like cells represent a new invaluable model for studying diabetes disease mechanisms. Here, we review the use of hPSC-derived β-like cells as a platform to model various types of defects in human β-cells in diabetes, comparing them against existing animal models, ex vivo human islets and human β-cell line. We also discuss how hPSC-derived β-like cells are being used as a platform for screening novel therapeutic compounds. Last but not least, we evaluate the strengths and limitations of this human cell-based platform as an avenue to study and reveal new insights into human β-cell biology.Entities:
Keywords: Beta cell; Diabetes; Disease modelling; Human; Pancreas; Pluripotent stem cell; iPS
Mesh:
Year: 2019 PMID: 31757584 DOI: 10.1016/j.semcdb.2019.11.004
Source DB: PubMed Journal: Semin Cell Dev Biol ISSN: 1084-9521 Impact factor: 7.727